Comparison of Different Self-Sampling Devices for Molecular Detection of Human Papillomavirus (HPV) and Other Sexually Transmitted Infections (STIs): A Pilot Study.
HPV (human papillomavirus)
acceptability
clinical accuracy
high-risk human papillomavirus (hrHPV)
self-collected samples
sexually transmitted infections (STIs)
vaginal self-sampling devices
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
28 Feb 2022
28 Feb 2022
Historique:
received:
31
12
2021
revised:
18
02
2022
accepted:
25
02
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Cervical cancer is the fourth most common cancer in women, and it is well known that high-risk human papillomavirus (hrHPV) infections are the necessary carcinogenic factors for the development of cervical tumors. Moreover, the interaction between HPV and other sexually transmitted infections (STIs) may increase the risk of cancer progression. Self-sampling has been demonstrated to represent a valid and well-accepted alternative, favoring women's participation in screening programs. This study aimed to investigate the use of FLOQSwabs Cervical and vaginal self-samples were collected, using two different combinations of vaginal self-sampling devices, from 40 women referred to colposcopy for a documented abnormal Pap smear. All samples were tested for hrHPV and seven STI pathogens using two commercial molecular assays. Data on hrHPV detection from the first group of women showed an almost perfect agreement (kappa: 0.89) between cervical vs. FS vaginal self-samples, and a substantial agreement (kappa: 0.79) between cervical and HerSwab™ (HS) samples. In the second group of women, an almost perfect agreement (kappa: 0.90) was demonstrated in the detection of hrHPV between cervical samples vs. FS, and a moderate agreement (kappa: 0.60) for cervical vs. Evalyn Evaluation of the three different vaginal self-collection devices confirmed their overall good acceptability by the studied population, as well as a similar agreement for hrHPV detection as compared to cervical samples. Our study indicated that the use of self-collected samples offers an alternative strategy to improve women's participation in cervical cancer screening programs, but also underlined the importance of evaluating the concordance in hrHPV detection of collection devices in combination with the molecular hrHPV assay.
Sections du résumé
BACKGROUND
BACKGROUND
Cervical cancer is the fourth most common cancer in women, and it is well known that high-risk human papillomavirus (hrHPV) infections are the necessary carcinogenic factors for the development of cervical tumors. Moreover, the interaction between HPV and other sexually transmitted infections (STIs) may increase the risk of cancer progression. Self-sampling has been demonstrated to represent a valid and well-accepted alternative, favoring women's participation in screening programs. This study aimed to investigate the use of FLOQSwabs
METHODS
METHODS
Cervical and vaginal self-samples were collected, using two different combinations of vaginal self-sampling devices, from 40 women referred to colposcopy for a documented abnormal Pap smear. All samples were tested for hrHPV and seven STI pathogens using two commercial molecular assays.
RESULTS
RESULTS
Data on hrHPV detection from the first group of women showed an almost perfect agreement (kappa: 0.89) between cervical vs. FS vaginal self-samples, and a substantial agreement (kappa: 0.79) between cervical and HerSwab™ (HS) samples. In the second group of women, an almost perfect agreement (kappa: 0.90) was demonstrated in the detection of hrHPV between cervical samples vs. FS, and a moderate agreement (kappa: 0.60) for cervical vs. Evalyn
CONCLUSION
CONCLUSIONS
Evaluation of the three different vaginal self-collection devices confirmed their overall good acceptability by the studied population, as well as a similar agreement for hrHPV detection as compared to cervical samples. Our study indicated that the use of self-collected samples offers an alternative strategy to improve women's participation in cervical cancer screening programs, but also underlined the importance of evaluating the concordance in hrHPV detection of collection devices in combination with the molecular hrHPV assay.
Identifiants
pubmed: 35326937
pii: healthcare10030459
doi: 10.3390/healthcare10030459
pmc: PMC8950387
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Cancer. 1989 May 15;43(5):805-9
pubmed: 2714885
Int J Environ Res Public Health. 2019 Sep 11;16(18):
pubmed: 31514378
J Int Med Res. 2019 Nov;47(11):5548-5559
pubmed: 31533513
Sex Transm Infect. 2002 Aug;78(4):278-81
pubmed: 12181467
PLoS One. 2015 Jul 13;10(7):e0132776
pubmed: 26168051
Expert Rev Anti Infect Ther. 2011 Feb;9(2):183-94
pubmed: 21342066
Pan Afr Med J. 2014 Mar 11;17:189
pubmed: 25396015
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
J Natl Cancer Inst. 2012 Feb 8;104(3):178-88
pubmed: 22271765
BMJ. 2018 Dec 5;363:k4823
pubmed: 30518635
J Obstet Gynaecol. 2018 Apr;38(3):402-407
pubmed: 29385850
Sex Health. 2006 Dec;3(4):209-15
pubmed: 17112429
J Clin Pathol. 2002 Apr;55(4):244-65
pubmed: 11919208
Cancer Res Treat. 2021 Jul;53(3):829-836
pubmed: 33421987
Sex Transm Dis. 2002 Nov;29(11):647-54
pubmed: 12438900
Cancer Cytopathol. 2015 May;123(5):271-81
pubmed: 25931431
Front Public Health. 2018 Apr 09;6:77
pubmed: 29686981
Int J Gynaecol Obstet. 2021 Jan;152(1):12-18
pubmed: 33124048
Int J Environ Res Public Health. 2021 Oct 02;18(19):
pubmed: 34639688
J Womens Health (Larchmt). 2017 Jun;26(6):609-615
pubmed: 28332888
Radiol Oncol. 2021 Jan 06;55(2):187-195
pubmed: 33764704
Sex Transm Dis. 2007 Jul;34(7):421-8
pubmed: 17091118
Int J Environ Res Public Health. 2019 Dec 09;16(24):
pubmed: 31818033
Int J Gynaecol Obstet. 2020 May;149(2):219-224
pubmed: 32037539
Biores Open Access. 2019 Apr 30;8(1):65-73
pubmed: 31057989
Sex Transm Dis. 2018 Jul;45(7):488-493
pubmed: 29465667
J Clin Virol. 2018 Oct;107:52-56
pubmed: 30195193
Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72
pubmed: 22828243
Lancet Oncol. 2014 Feb;15(2):172-83
pubmed: 24433684
Sex Transm Dis. 2019 Oct;46(10):670-675
pubmed: 31517806
Gynecol Oncol. 2014 Dec;135(3):487-94
pubmed: 25284037
Sex Transm Infect. 2011 Mar;87(2):118-22
pubmed: 21115503
Gynecol Oncol. 2014 Aug;134(2):302-8
pubmed: 24905772
J Gynecol Oncol. 2019 Sep;30(5):e76
pubmed: 31328458
Medicine (Baltimore). 2016 Mar;95(13):e3077
pubmed: 27043670
J Fam Plann Reprod Health Care. 2015 Oct;41(4):248-54
pubmed: 25583124